Mohammad Amin Manavi

Dr. Mohammad Amin Manavi

Tehran University of Medical Sciences, Tehran, Tehrān, Iran
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 March 2025 in International Immunopharmacology
Verified
Journal Article
Closed access
MMMohammad Amin Manavi
Mohammad Amin Manavi
RJRazieh Mohammad Jafari
Razieh Mohammad Jafari
HSHamed Shafaroodi
Hamed Shafaroodi
ADAhmad reza Dehpour
Ahmad reza Dehpour


2 November 2022 in Heliyon
Verified
Journal Article
Open access
MMMohammad Amin Manavi
Mohammad Amin Manavi
RJRazieh Mohammad Jafari
Razieh Mohammad Jafari
HSHamed Shafaroodi
Hamed Shafaroodi
SEShahram Ejtemaei-Mehr
Shahram Ejtemaei-Mehr
MSMohammad Sharifzadeh
Mohammad Sharifzadeh
ADAhmad reza Dehpour
Ahmad reza Dehpour
Ivermectin (IVM) is an antiparasitic medicine that exerts its function through glutamate-gated chloride channels and GABAA receptors predominantly. There is paucity of information on anti-seizure activity of IVM. Moreover, the probable pharmacological mechanisms underlying this phenomenon have not been identified. In this study, pentylenetetrazole (PTZ)-induced clonic seizures and maximal electroshock (MES)-induced tonic-clonic seizure models, respectively in mice was utilized to inquire whether IVM could alter clonic seizure threshold (CST) and seizure susceptibility. To assess the underlying mechanism behind the anti-seizure activity of IVM, we used positive and negative allosteric modulators of GABAA (diazepam and flumazenil, respectively) as well as KATP channel opener and closer (cromakalim and glibenclamide, respectively). Data are provided as mean ± S.E.M. After the performance of the variance homogeneity test, a one-way and two-way analysis of variance was used. Fisher's exact test was performed in case of MES. P-value less than 0.05 considered statistically significant. and Discussion: Our data showed that IVM (0.5, 1, 5, and 10 mg/kg, i.p.) increased CST. Furthermore, flumazenil 0.25 mg/kg, i.p. and glibenclamide 1 mg/kg, i.p., could inhibit the anticonvulsant effects of IVM. Supplementary, an ineffective dose of diazepam 0.02 mg/kg, i.p. or cromakalim 10 μg/kg, i.p. were able to enhance the anticonvulsant effects of IVM. Besides, we figure out that the IVM (1 and 5 mg/kg, i.p.) could delay the onset of first clonic seizure and also might decrease the frequency of clonic seizures induced by PTZ (85 mg/kg, i.p.). Finally, IVM could prevent the incidence and death in MES-induced tonic-clonic seizures. Based on the obtained results, it can be concluded that IVM may exert anticonvulsant effects against PTZ- and MES-induced seizures in mice that might be mediated by GABAA receptors and KATP channels.

16 November 2022 in Neurochemical Research
Verified
Journal Article
Closed access
PDF file
SJSina Jourian
Sina Jourian
MRMohammad Rahimi
Mohammad Rahimi
MMMohammad Amin Manavi
Mohammad Amin Manavi
MFMohammad Taha Pahlevan Fallahy
Mohammad Taha Pahlevan Fallahy
RJRazieh Mohammad Jafari
Razieh Mohammad Jafari
ADAhmad reza Dehpour
Ahmad reza Dehpour

25 February 2025 in Pharmacology Research & Perspectives
Verified
Journal Article
Open access
MBMohammad Balabandian
Mohammad Balabandian
MMMohammad Amin Manavi
Mohammad Amin Manavi
ALAli Lesani
Ali Lesani
RJRazieh Mohammad Jafari
Razieh Mohammad Jafari
HSHamed Shafaroodi
Hamed Shafaroodi
ADAhmad reza Dehpour
Ahmad reza Dehpour
Epilepsy, a chronic neurological disorder affecting around 65 million people globally, is characterized by recurrent, unprovoked epileptic seizures. Psilocin, the active metabolite of psilocybin, a well‐known psychedelic compound, has recently gained attention for its potential antidepressant and anxiolytic properties. This study aims to investigate the anticonvulsant effects of psilocin. The study utilizes behavioral seizure models and electrophysiological recordings in mice to assess the anticonvulsant efficacy of psilocin. The pentylenetetrazole (PTZ) test for clonic seizures and the maximal electroshock (MES) test for generalized tonic–clonic seizures are employed. Cortical electrical activity is monitored to provide insights into the compound's effects on neuronal activity. The involvement of kynurenine pathway, opioidergic and nitrergic systems, as well as cannabinoid receptors using agonist/antagonist paradigms. Western blotting was employed to evaluate the expression levels of key receptors and enzymes implicated in psilocin's anticonvulsant effects. The findings indicate a possible modulation of seizure activity by psilocin, with modest doses (3 mg/kg, i.p.) demonstrating potential anticonvulsant effects. Remarkably, the administration of 1‐MT, L‐NAME, naltrexone, sildenafil, and AM‐251 led to a diminishment of the anticonvulsant effects of psilocin, underscoring the involvement of the kynurenine pathway, nitrergic and opioidergic systems, cGMP, and the CB1 receptor in mediating the anticonvulsant effects of psilocin, respectively. Based on western blotting analysis, the upregulation of 5‐HT1A but not 5‐HT2A and the downregulation of IDO and CB1 expression following psilocin administration were observed. Acute administration of psilocin exerts anticonvulsant effects that might be mediated at least in part through the kynurenine pathway, opioidergic, serotonergic, and nitrergic systems.

27 January 2025 in Pharmacological Reports
Verified
Journal Article
Closed access
PDF file
ALAli Lesani
Ali Lesani
FBFatemeh Mashaknejadian Behbahani
Fatemeh Mashaknejadian Behbahani
MMMohammad Amin Manavi
Mohammad Amin Manavi
RJRazieh Mohammad Jafari
Razieh Mohammad Jafari
HSHamed Shafaroodi
Hamed Shafaroodi
ADAhmad reza Dehpour
Ahmad reza Dehpour